Medicare GLP-1 Bridge (2026)
A temporary CMS demonstration that gives eligible Medicare Part D enrollees GLP-1 weight-loss medication for a flat $50 a month, from July 1, 2026 through December 31, 2027.
The Medicare GLP-1 Bridge is a CMS demonstration that gives eligible Medicare Part D enrollees access to selected brand-name GLP-1 obesity medications for $50 per month from July 1, 2026 through December 31, 2027. It runs nationwide and is separate from the Part D benefit, so Part D plans do not have to opt in for eligible beneficiaries to gain access. The $50 copay does not count toward the Part D deductible or the annual out-of-pocket cap.
How the Medicare GLP-1 Bridge works
The Bridge is a nationwide CMS demonstration that sits outside the regular Part D benefit. Eligible Part D enrollees gain access automatically, so a plan does not have to opt in.
Bridge timeline
- July 1, 2026Medicare GLP-1 Bridge begins
Eligible Medicare Part D enrollees can access selected GLP-1 obesity medications for a flat $50 per month. The demonstration runs nationwide and is separate from the Part D benefit, so plans do not have to opt in.
- December 31, 2027Bridge demonstration ends
The Bridge is temporary. CMS uses the utilization data it collects during the demonstration to inform any longer-term program.
- Announced April 21, 2026Longer-term BALANCE Medicare model delayed
CMS announced an indefinite delay of the BALANCE Model's Medicare Part D component. The Bridge remains the active Medicare pathway for now; there is no confirmed successor date.
Who may be eligible
CMS sets three clinical paths. You need to meet one of them.
Qualifies on BMI alone. No additional diagnosis required.
With heart failure, uncontrolled hypertension, or chronic kidney disease.
With pre-diabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease.
Eligibility is based on your BMI and health history at the time you started GLP-1 therapy, not necessarily your BMI today. Your prescriber confirms which path applies.
Covered medications
The Bridge covers selected brand-name obesity GLP-1s. Compounded versions are not covered.
All formulations covered.
KwikPen formulation covered.
All formulations covered.
What Medicare still does not cover
- Compounded GLP-1 medications.
- Ozempic and Mounjaro for weight loss. They remain covered only for Type 2 diabetes.
- The $50 copay does not count toward your Part D deductible or the $2,100 annual out-of-pocket cap.
- People who are not enrolled in Medicare Part D.
Medicare vs commercial savings cards
Savings work differently on Medicare than on a commercial plan.
Commercial insurance
Manufacturer savings cards from Novo Nordisk and Eli Lilly can lower copays for commercially insured patients. These cards are not available to people with Medicare.
Medicare GLP-1 Bridge
Manufacturer savings cards are not available to Medicare beneficiaries. The Bridge sets a flat $50 monthly copay that does not increase as your dose increases, and it replaces rather than stacks with commercial coupons. That $50 does not count toward the Part D deductible or the $2,100 annual out-of-pocket cap.
Common questions
Sources & further reading
Coverage details are taken from the CMS Medicare GLP-1 Bridge program pages and KFF analysis, verified 2026-05-31. The Bridge is a temporary CMS demonstration running July 1, 2026 through December 31, 2027. Confirm your eligibility and current details with Medicare or your prescriber.